GlycoNex Incorporation (TPEX:4168)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
24.00
-1.05 (-4.19%)
At close: Mar 9, 2026
-0.41%
Market Cap 2.60B
Revenue (ttm) 36.63M
Net Income (ttm) -217.59M
Shares Out 108.21M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 205,455
Average Volume 370,552
Open 22.70
Previous Close 25.05
Day's Range 22.70 - 24.00
52-Week Range 15.60 - 30.95
Beta 0.59
RSI 32.46
Earnings Date Mar 13, 2026

About GlycoNex Incorporation

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed antibody drug currently under the lead optimization stage; and GNX1021, a first-in-class antibody–drug conjugate currently under preclinical stage. It is a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4168
Full Company Profile

Financial Performance

In 2024, GlycoNex Incorporation's revenue was 14.70 million, an increase of 478.32% compared to the previous year's 2.54 million. Losses were -229.71 million, 28.8% more than in 2023.

Financial Statements

News

There is no news available yet.